News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|December 1, 1999

New Products for pediatrics: 1999

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Top 5 pediatric health headlines you missed in May 2026 | Image Credit: © sebra - stock.adobe.com.

Top 5 pediatric health headlines you missed in May 2026

ByMorgan Ebert, Executive Editor

June 3rd 2026

Supporting children with hidradenitis suppurativa beyond medical treatment, with Colleen Cotton, MD

Supporting children with hidradenitis suppurativa beyond medical treatment, with Colleen Cotton, MD

ByColleen Cotton, MD, FAAD

June 3rd 2026

Julie Khlevner, MD, discusses the impact of FDA-approved LINZESS for functional constipation

Julie Khlevner, MD, discusses the impact of FDA-approved LINZESS for functional constipation

ByJulie Khlevner, MD, AGAF

June 3rd 2026

FDA approves ensitrelvir for post-exposure prevention of COVID-19 in adolescents and adults

FDA approves ensitrelvir for post-exposure prevention of COVID-19 in adolescents and adults

ByMorgan Ebert, Executive Editor

June 2nd 2026

Recognizing the skin findings that distinguish pediatric hidradenitis suppurativa

Recognizing the skin findings that distinguish pediatric hidradenitis suppurativa

ByColleen Cotton, MD, FAAD

June 2nd 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

Julie Khlevner, MD, discusses the impact of FDA-approved LINZESS for functional constipation

FDA approves ensitrelvir for post-exposure prevention of COVID-19 in adolescents and adults

Recognizing the skin findings that distinguish pediatric hidradenitis suppurativa

Colleen Cotton, MD, on the importance of early recognition in hidradenitis suppurativa

FDA accepts mavacamten (Camzyos) application for adolescent obstructive hypertrophic cardiomyopathy